Group items tagged

The Fitness-to-Practise Committee of the General Pharmaceutical Council has issued a three-month suspension to Mohammed Roohul Haque (Reg No: 2226084), a locum pharmacist, due to incidents of workplace sexual misconduct. According to the determination document issued by the regulatory body, Haque undertook the position of a locum pharmacist at Hollowood Chemists on July 12. It was during this period that he encountered the dispenser (referred to as the "complainant"), a 40-year-old co-worker at the pharmacy, for the first instance. Following this initial meeting, he proceeded to engage in making explicit sexual comments. During the lunch break of the pharmacy's second dispenser, Haque asked the dispenser, who had lodged the complaint, to review photographs displayed on his mobile phone, depicting renovations being carried out at his residence. The initial images focused on the ongoing renovation activities. However, he later switched to displaying a full-screen photograph of his erect penis, the document said. Despite the fact that the dispenser promptly distanced herself, Haque persisted in discussing the photograph with her. He went so far as to apologise, and even asked if she had managed to closely observe the picture.

A couple in Maidenhead, Berkshire has been handed suspended sentence for illegal possession and supply of £1.6m of unlicensed medicines. Following investigations initiated by the MHRA, Karina Filimonova and Andrejs Stolarovs were caught with the unlicensed medicines which included prescription-only medications. Southwark Crown Court sentenced each "to eight months imprisonment suspended for 18 months and 150 hours unpaid work" for possessing and intending to supply medicinal products contrary to the Human Medicines Regulations 2012. "This was a sophisticated operation illegally bringing unlicensed medicines into the UK from Singapore and India, and then distributing them across the country and abroad," said Andy Morling, MHRA Deputy Director of Criminal Enforcement. "Criminals trading in medicines illegally like this are not only breaking the law, but they also have no regard for your safety. These are powerful medicines that can lead to serious adverse health consequences if taken without appropriate medical supervision." In 2020, the Royal Mail Group (RMG) informed the MHRA about parcels containing unlicensed medicines discovered during their investigation into suspicious parcel activity. Following this, the MHRA's Criminal Enforcement Unit, in cooperation with local police, launched an investigation and apprehended the couple at their residence in Kidwells Close, Maidenhead.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

The Medicines and Healthcare products Regulatory Agency's (MHRA) Criminal Enforcement Unit (CEU) has seized a quantity of suspected unlicensed medical products including unlicensed versions of Botox, numbing agents and dermal fillers in Bolton, Greater Manchester. Officers from the MHRA and Greater Manchester Police conducted a raid across nine addresses in Bolton, Westhoughton and Leigh in the early hours of Thursday 13 July 2023, where two women and a man were arrested. Andy Morling, MHRA Deputy Director of Criminal Enforcement said: "Medicines like these are powerful and dangerous in the wrong hands, potentially leading to serious adverse health consequences. The criminals trading in these products are not only breaking the law, they also have no regard for your safety. It is illegal to advertise, sell or supply medicines such as these without the appropriate authorisation. If you see these products, or any other powerful medicines, being sold on social media or elsewhere online, think. It's unlikely to be legitimate. You can help the MHRA take action by reporting concerns to us through our Yellow Card scheme.

The National Pharmacy Association (NPA) is calling on NHS England and its member to pause and reflect before further implementing the pharmacy contraception service. NPA board met on Tuesday (25 April) to discuss the Pharmacy Contraception Service and the board decided that - with the community pharmacy sector at breaking point - it cannot support the immediate roll out of this service. The association believes that with no new funding for the service, and all existing funds in effect already allocated to other pharmacy activity, any payments to the sector for delivery of the oral contraception service will ultimately be clawed back by NHS England. Tweeting after the meeting yesterday, the NPA said: "We can't tell pharmacy owners what they can and can't do. But we can tell them the facts; fact number one is that with no new funding currently available everyone will be a loser from the implementation of this service on the current terms." NPA Vice-Chair Jay Badenhorst added: "We cannot be expected to take on more and more services without the increase in funding necessary to deliver them effectively. Meanwhile, taking on additional work when current workload already exceeds capacity risks impacting negatively on the overall quality of care people experience in pharmacies. We still believe this could, in future, be a great new pharmacy service, but not without the extra funding necessary to deliver it safely and effectively. We want to offer women this extra support, but if it's worth doing it's worth doing properly."

The European Commission said on Wednesday it would allocate 1.23 billion euros ($1.3 billion) to mental health initiatives across the 27-member European Union and make mental health a pillar of health policy. "Today marks a new beginning for a comprehensive, prevention-oriented and multi-stakeholder approach to mental health at EU level," Stella Kyriakides, EU Commissioner for health and food safety, said in a statement. "We need to break down stigma and discrimination so that those in need can reach out and receive the support they need. It is OK not to be OK, and it is our duty to ensure that everyone asking for help has access to it." The Commission said mental health problems already impacted around 84 million people before the COVID-19 pandemic with an economic cost of about 600 billion euro a year, or 4% of the bloc's GDP. The situation has deteriorated since the pandemic with the war in Ukraine, climate change anxiety and the rising cost of living due to soaring inflation. At a press conference, Commission vice-president Margaritis Schinas called it a "silent epidemic" and said the topic was the last piece in the European Health Union "puzzle".

Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.

If you're looking for the best probiotic brands, you've come to the right place. In this blog post, we will discuss how to find the right probiotic brands for your needs. We'll go over factors such as price, quality, and customer reviews to help you make an informed decision. We will also discuss the different types of probiotics and how to select the right one for you. So whether you're just starting out on your probiotic journey or you're looking for a new brand to try, read on for our top tips! HOW TO CHOOSE A PROBIOTIC BRAND? When choosing a probiotic brand, it's important to consider factors such as price, quality, and customer feedback. Price is often the first factor people consider when selecting a probiotic brand. However, it's important to remember that cheaper is not always better. Quality should be your main priority - some brands may be more expensive but offer superior probiotic strains with higher concentrations of beneficial bacteria compared to others. A probiotic should contain at least 10 Billion CFUs (colony-forming units) to be considered effective. The ingredients it should have are lactic acid bacteria, bifidobacteria, and Enterococcus. So , these probiotics are good for gut health and digestion. In addition, they should consist of bacterial strains that are resistant to stomach acid and bile, as these can break down beneficial bacteria before they reach the gut.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

Living in challenging times means that the world seems to be constantly changing, and it can be hard to keep up. Along with all the other challenges you face, it's more important than ever to stay healthy. But what does that mean for you? What are the health tips that everyone should follow? There's a lot of information out there about health and wellness, and it can be overwhelming trying to figure out what's best. That's why you should check this list of the top seven health tips that everyone should follow. GET REGULAR EXERCISE Everyone needs to make time for physical activity and aim for at least 150 minutes of moderate-intensity exercise each week. This can be anything from walking or swimming to dancing or aerobics classes. Exercise not only strengthens your body, but it can also help you manage stress and improve your mood, while also boosting your immune system. If, for any reason, you're not able to get the recommended amount of exercise, try breaking up activities into smaller chunks and incorporating them into your daily routine.

A total of 525 candidates have passed the common registration assessment for pharmacists held in November, the regulators GPhC and PSNI have announced on Tuesday. With 937 candidates sitting for the registration assessment, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI) on 3 November, the pass rate was 56 per cent, down from the 61 per cent for the Autumn 2021. Among the GPhC candidates, 59 per cent were sitting for the first time, 30 per cent for the second time and 8 per cent for the third time. (The break-up was not available for the 3 per cent PSNI candidates.) In comparison, for the June sitting 89 per cent of candidates were sitting for the first time, 7 per cent were sitting for the second time and 4 per cent were sitting for the third time. "We would like to congratulate the successful candidates and we look forward to them joining our register and continuing to the next stage of their career," Duncan Rudkin, GPhC chief executive said.

Leaders from across the pharmacy sector and trade bodies dwelled on the challenges faced by the pharmacists at the Sigma Conference held on Sunday (2 October). "If the cost of carrying out regulation is higher than the benefits, it's time for all the bodies to sit together and talk on what can be adjusted accordingly," said Salim Jetha, Chairman, Avicenna. Jetha highlighted the challenges faced by the independent pharmacy and also raised the concern about the 'level playing field' for pharmacists compared to GPs. He said: "GPs get paid for energy cost, premises cost, the staffing cost. We don't get paid for that. So don't be misled by saying we are being exactly the same. Yes, on paper we are, but in reality we are not. I think also the rules of engagement are different." He called for better collaboration with GPs, and urged PSNC and other trade bodies to ensure a level playing field. Janet Morrison, CEO, Pharmaceutical Services Negotiating Committee(PSNC), warned that the pressure in the sector is building up to a 'breaking point'.

The pharmacy bodies have expressed a deep concern over Lloyds Pharmacy's announcement on plans to close all pharmacy branches located in Sainsbury's before the end of 2023. Pharmaceutical Services Negotiating Committee (PSNC) Chief Executive Janet Morrison said: "This significant shrinkage by the second largest pharmacy chain is an extremely worrying development and one of the clearest signals yet of just how much all community pharmacies are struggling to make ends meet. We know that many are at breaking point." She added: "We understand that LloydsPharmacy will be in touch directly with affected staff and patients at this difficult time. As these pharmacies close, other pharmacies locally will be braced for even more pressures as they try to cope with increased demand." "The announcement by LloydsPharmacy will be of concern to staff, patients, the public and the community pharmacy sector alike," Malcolm Harrison, Chief Executive of the Company Chemists' Association (CCA). Pharmacists, and other employees, working at pharmacies owned and operated by LloydsPharmacy in Sainsbury's have been told that the group of more than 200 pharmacies will be closed this year as LloydsPharmacy will be ending their relationship with the supermarket chain.

You work hard for your money, so you should make sure that when something terrible happens - like a car accident or a fire in your home - you're fully compensated. That's where insurance comes in. But sometimes, the premiums for good coverage can be expensive. So how do you get the best deal on insurance without compromising your peace of mind? It all starts with knowing how to haggle. Insurance companies are always looking for new customers and want to make as much profit as possible on each one. That means they're often willing to negotiate on price. But you have to know what to say and how to say it. Here are a few tips. DEFINE WHAT YOU WANT IN MIND The first step is to understand what you want from your insurance policy. What kind of coverage do you need? How much are you willing to pay? When you know the answers to these questions, it's easier to start negotiating with insurers. This precise information will also help you during the application process. Many insurance companies will ask you questions about your needs. The more specific you can be, the better your chance of getting a policy that meets your needs without breaking your budget.

Professor Harry McQuillan has said community pharmacists in the UK must change their focus from an 'accuracy of supply' to a 'safety of supply' model when it comes to dealing with patients. "The main take away message from tonight's lecture is for pharmacy professionals to really challenge themselves about whether they are focused on accuracy of supply or safety of supply," he said at this year's UCL School of Pharmacy Lecture in London on Thursday, 15 June. "For our community pharmacists it must be about safety, including prescribing, and ensuring patients and citizens get the maximum benefit from prescribed medicines. "To deliver this, we need to invest in our teams - harness technology and always be willing to take the next step in a more clinical future." The Chief Executive Office of Community Pharmacy Scotland, however, noted that at a time when the UK was grappling with an unprecedented national debt crisis exacerbated by severe cost of living and spiraling inflation, community pharmacy will need to make a "compelling case" of where the priority should be in the sector. Expanding on the financial woes of the country, he compared the current national debt of the UK, which stood at a staggering 270 percent of GDP in September 2022, with the previous record-breaking national debt of 250 per cent at the end of WWII.

The consequences of NHS workforce crisis is not limited to general practice, community pharmacies are also suffering, commented Community Pharmacy England after the General Medical Council (GMC) published a report on Friday (23 June) which warned of the burnout in the workforce. The report calls for urgent actions to break a 'vicious cycle' of unmanageable workloads, dissatisfaction and burnout that is causing UK doctors to take steps to quit. Chief Executive Janet Morrison, said: "The GMC's report is yet another clear signal of the scale of the mounting the NHS workforce crisis, and this is not limited to general practice: community pharmacies are also suffering the consequences of it." "Pharmacy teams are overstretched, feeling immense pressures, and dealing with significantly increased workloads. Pharmacy owners are also finding it impossible to make ends meet, not least given the rising staffing costs which are being driven up by workforce issues. Findings show the number of doctors who reported working beyond their rostered hours on a weekly basis rose from 59% in 2021 to 70% in 2022, and 42% said they felt unable to cope with their workload each week (up from 30% in 2021). Just half said they were satisfied in their work, down from 70% in 2021.

The Department of Health and Social Care (DHSC) has included Tibolone 2.5mg tablets (Livial) and Prasterone 6.5mg pessaries (Intrarosa) to the list of Hormone Replacement Therapy (HRT). It has updated the June 2023 Drug Tariff (Part XVI) to include these additional HRT medicines for which patients will be able to purchase an HRT PPC. "HRT is the replacement of female sex hormones oestrogen and progesterone in women to control symptoms of the menopause. Some medicines that are converted or break down into oestrogen, progestogen or androgen hormones are prescribed for relief of menopausal symptoms. For the purposes of the HRT PPC these are included within this definition of HRT," said DHSC.

We are over the moon to break the news that your favourite health supplement brand in India got recognition as the "Top 10 Best Nutraceuticals Startups In India - 2022.

With GP waiting times on the rise and the secondary NHS care system under pressure, there is a further opportunity for pharmacy to support the general public with self-care. The men's health category is one category where pharmacists can play a leading role - specifically Erection Problems (EPs) where pharmacists can be key to building awareness, destigmatising the condition, and providing support and solutions for the patient. Training for pharmacists is essential - helping them to understand how they can assist those looking for treatment whilst also breaking down barriers and normalising the conversation around EPs. EPs are when a man regularly cannot get and keep an erection. EPs can happen to any adult man, not limited to the older generation, though they are particularly common in men over the age of 40. EPs may happen in some situations over others and so it is increasingly important for men to speak about and identify the cause of their symptoms, particularly because EPs can often be an indication of other serious health conditions like cardiovascular disease, high blood pressure or diabetes. If pharmacies can encourage men to seek help with their EPs, they may also be able to identify additional serious and undiagnosed conditions earlier, thereby supporting men's health more widely.

Community pharmacy teams in England have broken all previous records by a distance and delivered nearly five million flu jabs in the past season. They have administered over 2.08 million more flu vaccinations under the national programme during 2021-22 than the previous year, which is a a 75 increase, the Pharmaceutical Services Negotiating Committee has reported. According to latest data published by the NHS Business Services Authority in its Advanced Service Flu report community pharmacy has administered 4.85 million vaccinations under the national Flu Vaccination Service in 2021-22. The total number of vaccines administered in community pharmacies in 2020-21 was 2.77 million. Commenting on the end-of-season figures, PSNC chief executive Janet Morrison said: "I am thoroughly impressed to hear it confirmed that community pharmacy has had another record-breaking year of flu vaccination provision. The ability of pharmacy teams to deliver the healthcare services that communities need, despite the challenges and pressures this winter, is simply phenomenal.